Last reviewed · How we verify
Generalized pustular psoriasis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Spevigo | SPESOLIMAB | Boehringer Ingelheim Pharmaceuticals Inc | Interleukin-36 Receptor Antagonist [EPC] | Interleukin-1 receptor-like 2 | 2022-01-01 | |
| SPEVIGO | SPESOLIMAB-SBZO | BOEHRINGER INGELHEIM PHARMACEUTICALS INC | Interleukin-36 Receptor Antagonist [EPC] | Interleukin-1 receptor-like 2 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- BOEHRINGER INGELHEIM PHARMACEUTICALS INC · 1 drug in Generalized pustular psoriasis
- Boehringer Ingelheim Pharmaceuticals Inc · 1 drug in Generalized pustular psoriasis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Generalized pustular psoriasis:
- Generalized pustular psoriasis treatment updates — RSS
- Generalized pustular psoriasis treatment updates — Atom
- Generalized pustular psoriasis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Generalized pustular psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/generalized-pustular-psoriasis. Accessed 2026-06-10.
Related
- Generalized pustular psoriasis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing